Market Intelligence, Clinical Progress, and High-Purity Reagents for Neutrophil Elastase-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ELANE drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ELANE Active Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View ELANE Products |
| Gene Delivery | ELANE Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View ELANE Products |
| Benchmark Ab | Anti-ELANE Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View ELANE Products |
| Validator | ELANE siRNA Set For target knockdown and specificity validation in cell-based models. |
View ELANE Products |
| Related Target A | PRTN3 (Proteinase 3) Homologous neutrophilic serine protease; essential for selectivity counter-screening. |
View PRTN3 Products |
| Related Target B | CTSG (Cathepsin G) Co-released with ELANE; critical for off-target profiling in inflammatory assays. |
View CTSG Products |
| Related Target C | CTSC (Cathepsin C / DPP1) Upstream activating protease responsible for processing and activating ELANE. |
View CTSC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human vs. Rodent differences) | Human, Mouse, and Rat ELANE ortholog proteins available with >95% purity and verified molecular weight. |
| Subfamily Serine Protease Selectivity | PRTN3 and CTSG homolog panel proteins strictly verified by mass spectrometry to eliminate cross-contamination. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies and high-activity enzymes included in the catalog. |
| False Positives in Small Molecule Screens | Sequence-verified siRNA sets included for target knockdown and specificity verification. |
Live ELANE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ELANE (Neutrophil Elastase) therapeutics is intensifying, with major players shifting focus from traditional systemic small-molecule inhibitors to inhaled formulations and highly selective monoclonal antibodies. As first-generation non-selective serine protease inhibitors reach clinical maturity, the next wave of R&D is targeting precise tissue-localized inhibition and upstream regulation via DPP1 (Cathepsin C) inhibition. Managing neutrophilic inflammation without compromising systemic host defense remains the primary engineering challenge.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhaled/Oral) | Insmed, Santhera, Boehringer Ingelheim | Bronchiectasis, COPD, ARDS, Cystic Fibrosis | Enzymatic Inhibition Assay (Requires active, high-purity ELANE protein) |
| Monoclonal Antibodies | Academic & Biotech Consortia | Acute Lung Injury, Cancer Metastasis | Epitope Mapping & SPR Binding (Requires native glycosylation HEK293-expressed ELANE) |
| Upstream Inhibitors (DPP1) | Insmed (Brensocatib) | Non-Cystic Fibrosis Bronchiectasis | Activation Assay (Requires recombinant CTSC/DPP1 and pro-ELANE) |
Title: ELANE/ELA2/Neutrophil Elastase Reagents & Market Landscape | TarMart Description: Buy high-purity ELANE (Neutrophil Elastase) active proteins, biosimilar antibodies, and siRNA. Explore clinical pipelines and assay solutions for COPD and Bronchiectasis. Keywords: ELANE protein, Neutrophil Elastase inhibitor, ELA2 recombinant protein, PRTN3, CTSG, Brensocatib assay, COPD drug discovery